|
ClonazepamKey points Drug misuse treatments work. Substantial numbers are affected by drug misuse across the UK who could benefit from interventions. Availability and engagement in treatment has been increasing substantially over the last decade. Psychopharmacology 152: 55, 200, for instance, clonazepam sexual side effects. Department of Pathology, First Military Medical University, Guangzhou, P.R. China More than hundreds of proteins have been reported to be involved in the regulations of metastasis in colorectal carcinoma CRC ; . However, all the known genetic alterations are not enough to explain fully the progression of CRC and genetic markers specific in CRC or its metastasis are little known. So it is necessary to discover the specific protein markers and understand their functions by proteomic tools. A pair of colorectal carcinoma cell lines SW620 and SW480 with different metastatic potentials, originated from the same parent was used in this study. The protein expressive spectrums of the two cell lines were obtained and optimized by using two dimensional gel electrophoresis. Then the differentially expressed protein spots associated with metastasis between them were analyzed by MelanieIII software. The 2-DE expressive spectrums of the two cell lines have good repetitivities and comparativities. The resolution ratio of 2-DE was increased after using the nonlinear PH310 or overlapping narrow IPG strips. After software analysis, 11 differentially expressed protein spots with high density and clear borderline were picked out to digest in gel and then identified by MS. Two proteins were primarily identified as nucleolar transcription factor1 NTF1 ; and tumor suppressor protein APC. Nonlinear PH310 and overlapping narrow IPG strips can improve the protein separating efficiency of 2-DE. The differentially expressed proteins separated primarily will lay the basis on identifying metastasis-associated proteins of colorectal carcinoma and establishing the 2-DE database of the metastatic colorectal carcinoma cell lines. Klonopin wafer clonazepam
Patients 40-75 years old who have two or more CAD risk factors and a newly diagnosed low LVEF 0.45 ; should be offered stress testing or coronary angiography within 3 months of the diagnosis of low LVEF unless an etiology of LV dysfunction other than CAD is documented in the medical record or they have contraindications to revascularization or they have had stress testing or coronary angiography within the 2 years prior to the diagnosis of low LVEF. AOCB A Timoney outlined SMC's exclusive role in the evaluation of medicines. She raised the matter of medical devices, which were not to be evaluated by SMC, and suggested that the DTC may wish to consider a process for dealing with devices. P Davey held the view that NMIP could assess an evaluation by another body, but not evaluate a device from the outset and cyclobenzaprine. Potential 1.5-3 fold clonazepam concentrations Contraindicated; possible clorazepate concentrations Contraindicated; possible diazepam concentrations. Substances in this schedule have a lower potential for abuse relative to substances in Schedule III. Examples of Schedule IV narcotics include propoxyphene Darvon and Darvocet-N 100 ; . Other Schedule IV substances include alprazolam Xanax ; , clonazepam Klonopin ; , clorazepate Tranxene ; , diazepam Valium ; , lorazepam Ativan ; , midazolam Versed ; , temazepam Restoril ; , and triazolam Halcion and depakote. SF-36 What it measures B A survey of general health well-being and functional states. Benefits B Assesses a broad spectrum of patient disability reports. Serial administrations could be used to track patient perceived functional changes during the course of treatment, and assess outcome, because purchase clonazepam. Oct. Teijin Biomedical Laboratory established in London and detrol. DRUG PROTONIX 40MG TABLET EC HYDROCODONE APAP 5 500 TAB FUROSEMIDE 40MG TABLET ALBUTEROL 90MCG INHALER ALPRAZOLAM 1MG TABLET RANITIDINE 150MG TABLET DOCUSATE SODIUM 100MG CAP ALPRAZOLAM 0.5MG TABLET AMBIEN 10MG TABLET ZOLOFT 100MG TABLET PLAVIX 75MG TABLET METFORMIN HCL 500MG TABLET PROPOXY-N APAP 100-650 TAB LIPITOR 10MG TABLET LEXAPRO 10MG TABLET ALLEGRA 180MG TABLET HYDROCODONE APAP 7.5 500 TB ZOLOFT 50MG TABLET CLONAZEPAM 1MG TABLET SINGULAIR 10MG TABLET CLONAZEPAM 0.5MG TABLET CLONIDINE HCL 0.1MG TABLET POTASSIUM CL 20MEQ TAB SA HYDROCODONE APAP 7.5 750 TB SEROQUEL 25MG TABLET NEURONTIN 300MG CAPSULE LORAZEPAM 0.5MG TABLET FUROSEMIDE 20MG TABLET DEPAKOTE ER 500MG TAB SA HYDROCHLOROTHIAZIDE 25MG TB PHENYTOIN SOD EXT 100MG CAP NORVASC 5MG TABLET FAMOTIDINE 20MG TABLET HYDROCODONE APAP 10 500 TAB RANITIDINE 150MG CAPSULE LORATADINE 10MG TABLET LORAZEPAM 1MG TABLET RISPERDAL 1MG TABLET LIPITOR 20MG TABLET MULTIVITAMIN TABLET NORVASC 10MG TABLET CYCLOBENZAPRINE 10MG TABLET SEROQUEL 100MG TABLET ZYRTEC 1MG ML SYRUP TRAZODONE 50MG TABLET FLUOXETINE 20MG CAPSULE ALPRAZOLAM 0.25MG TABLET LISINOPRIL 10MG TABLET COMBIVENT INHALER RISPERDAL 0.5MG TABLET TOTALS FOR TOP 50 DRUGS TOTALS FOR ALL DRUGS TOTAL CLAIMS SCREENED THERA CLASS D4K H3A R1M J5D H2F D4K D6S H2F H2E H2S M9P C4L H3A M4E H2S Z2A H3A H2S H4B Z4B H4B A4B C1D H3A H7T H4B H2F R1M H4B R1F H4B A9A D4K H3A D4K Z2A H2F H7T M4E C6Z A9A H6H H7T Z2A H7E H2S H2F A4D J5D H7T # ALERTS 4, 118 3, % OF TOTAL THIS CNFLT 1.237 1.121 1.091 # OF OVERRIDES 130 166 292 Initial Draft Prepared by ACS State Healthcare, PBM 2005 mlb 5 28 2005 The preparation of this document was financed under an agreement with Indiana OMPP. ECMO treatment does not predict mortality in patients with most severe ARDS. 2006 Springer-Verlag. 427. Effects of a backboard, bed height, and operator position on compression depth during simulated resuscitation - Perkins G.D., Smith C.M., Augre C. et al. [G.D. Perkins, University of Birmingham, Division of Medical Sciences, B15 2TT Birmingham, United Kingdom] - INTENSIVE CARE MED. 2006 32 10 ; - summ in ENGL Objective: To investigate the effect of a backboard, cardiopulmonary resuscitation CPR ; provider body position and bed height on the quality of chest compression during simulated in-hospital resuscitation. Design and setting: Randomised controlled cross-over trial in a university hospital. Participants: Second-year medical student basic life support instructors. Interventions: Chest compressions performed on a resuscitation manikin placed on a hospital bed with without a CPR backboard, kneeling on the bed adjacent to the manikin and lowering the height of the bed. Measurements and results: Sub-optimal chest compressions were performed on all surfaces. There were no differences in compression depth: standard CPR, 29 7 mm; backboard CPR, 31 10 mm; kneeling on the bed, 30 7 mm; lowering bed height, 32 10 mm. Compression rate and duty cycle were similar on each surface. Participants failed to recognise their poor quality CPR, and there was no difference in assessment of fatigue or efficacy of CPR between surfaces. Conclusions: In contrast to current guidelines, the use of a CPR backboard did not improve chest compressions. Furthermore, kneeling on the bed adjacent to the victim or lowering bed height did not impact materially on the quality of chest compression. These findings should be validated in clinical studies. 2006 Springer-Verlag. 428. Protective effects of PARP inhibition on liver microcirculation and function after haemorrhagic shock and resuscitation in male rats - Roesner J.P., Vagts D.A., Iber T. et al. [B. Vollmar, University of Rostock, Department of Experimental Surgery, Medical Faculty, Schillingallee 70, 18055 Rostock, Germany] - INTENSIVE CARE MED. 2006 32 10 ; - summ in ENGL Objective: The aim of this study was to investigate the impact of the water-soluble poly- ADP ; -ribose-polymerase PARP ; inhibitor 5- aminoisoquinolinone 5-AIQ ; on liver microcirculation and function after haemorrhagic shock and resuscitation. Design: Controlled, randomized animal study. Setting: University animal care facility and research laboratory. Subject: Male Sprague-Dawley rats were subjected to haemorrhagic shock for 1 h, followed by resuscitation with shed blood and crystalloid solution for a total of 5 h. Interventions: The PARP inhibitor 5-AIQ 3 mg kg; n 7 ; or vehicle n 7 ; was administered 5 min prior to resuscitation. Sham-operated animals without induction of shock served as controls n 7 ; . Measurements and results: Using intravital fluorescence microscopy hepatic microcirculation was assessed at baseline, end of shock phase as well as 1 h and 5 h after resuscitation. Systemic arterial blood pressure and bile flow were continuously monitored. 5-AIQ treatment attenuated shock resuscitation-induced increase of intrahepatic leukocyte-endothelial cell interaction with a marked reduction of both sinusoidal leukostasis and venular leukocyte adherence. Moreover, nutritive perfusion was found improved, guaranteeing sufficient oxygen supply to tissue, as indicated by low NADH autofluorescence, which was not different to that in controls. Most notably, excretory liver function reached baseline level over 5 h of reperfusion in 5-AIQ-treated animals. Conclusions: In the present setting of shock resuscitation in male rats the PARP inhibitor 5-AIQ proved to be very effective in ameliorating compromised liver microcirculation and function. Further research has to confirm that PARP inhibition is a suitable tool in the acute treatment of patients suffering from reduced circulating blood volume and thus microcirculatory organ dysfunction. 2006 Springer-Verlag. 429. Anesthetic management of a pregnant patient with dengue hemorrhagic fever for emergency cesarean section - Chhabra A. and Malhotra N. [A. Chhabra, Departments of Anesthesiology and Intensive Care, ] - INT. J. OBSTET. ANESTH. 2006 15 4 ; summ in ENGL Dengue fever is the most common and widespread insect-borne viral infection worldwide. The most critical phase of this viral Section 24 vol 42.2 and diazepam. Intraperitoneal Chemotherapy There are patients who present with intra-abdominal sarcomatosis and minimal other organ involvement. A review of the M.D. Anderson Cancer Center experience found that tumor volume was a prognostic factor. Patients with tumors 5 cm in diameter or 10 peritoneal nodules had a superior two year overall survival of 75%. On the other hand, only 14% of patients were alive at two years when their tumors were 5cm or they had 50 peritoneal nodules. Eilber at UCLA has used intraperitoneal mitoxantrone to treat 54 patients with intra-abdominal sarcomatosis, 33 of whom had GISTs. Mitoxantrone was chosen because it is an anthracycline that binds to intraperitoneal tissues and produces high local drug concentrations with minimal systemic absorption. Fifty-four patients were surgically debulked and then treated with intraperitoneal mitoxantrone. This approach was shown to be safe and technically feasible. The five year overall survival was 46% for patients with peritoneal only disease, while only 5% of those with liver metastases survived. In the 27 patients with peritoneum only disease, the median time to recurrence was increased from 8 months to 21 months by the addition of postoperative intraperitoneal mitoxantrone. However, after a median time of 11 months, 83% of patients had recurrent disease. Therefore, intraperitoneal chemotherapy may provide benefit for patients with peritoneum only disease. Additional studies with intraperitoneal chemotherapy for recurrent GIST are also being evaluated at MDACC for patients with imatinibresistant tumors. Systemic Chemotherapy Only since the availability of Kit immunohistochemistry and the unprecedented activity of imatinib has GIST been routinely distinguished from intra-abdominal leiomyosarcoma. Thus, interpretation of most chemotherapy trials of intra-abdominal soft tissue sarcoma is impossible. Presumptively, many if not most tumors classified in the past as gastrointestinal leiomyosarcoma were actually GIST. Until the development of imatinib there has been no standard therapy for GIST. Doxorubicin and ifosfamide are the two most active agents in sarcoma and the centerpiece of most regimens used to treat soft-tissue sarcomas. However, these two agents have very limited activity in patients with GIST. We reviewed our experience at M. D. Anderson Cancer Center with patients treated for GI leiomyosarcomas stomach and small bowel, presumably GISTs ; between 1948 and 1989. Of 120 patients with measurable disease and treated with a doxorubicin-based regimen, there were four objective responses one complete and three partial ; for an objective response rate of 3.3%. Three PRs were seen with CyaDic cyclophosphamide, doxorubicin, and DTIC ; , and one PR and one CR were seen with CyVADic cyclophosphamide, vincristine, doxorubicin, and DTIC ; [89]. We also reviewed our experience with ifosfamide in patients treated for GI leiomyosarcomas between 1985 and 1989. We found four objective responses in 30 patients with evaluable disease for a response rate of 13.3% [90]. This observation has been confirmed by investigators at Mayo. The Michigan Court of Appeals recent decision in Boodt v. Borgess Medical Center, et al., has a little something for everyone. There's MCL 600.2912b, Roberts v. Mecosta County Gen. Hosp. After Remand ; and a published opinion for the notice of intent NOI ; buffs, and MCL 600.5852, Eggleston v. Bio-Medical Applications of Detroit, Inc., and McLean v. McElhaney, et al., for those folks who can't get enough of the "second-bite-at-theapple" issues that arise in the context of appointing successor personal representatives. As if that weren't enough, there's also a call for the convening of a special conflict panel, some discussion of the Probate Code and a possible res judicata question. What prompted this convergence of issues was the trial court's dismissal with prejudice of personal representative MelisOne more chance sa Boodt's wrongful death medical-malpractice lawsuit. Of the plaintiff 's argument Pursuant to a summary dispo- that the dismissal of her case sition motion filed by Dr. Michael against the medical facilities Andrew Lauer, Borgess Medical should be "without prejudice so Center and Heart Center for ExContinued on page 6 and diflucan and clonazepam, for instance, clonazeppam dog dose. 12. Product or Service Brochure Anderson DDB San Francisco LifeScan, Inc. a Johnson & Johnson Company ; 13. Brand Reminder Item Medical Broadcasting Company MBC ; Amgen Wyeth 14. Sales Force Training Motivation Eric Mower and Associates Welch Allyn 15. Convention Exhibit Design Photosound Communications GlaxoSmithKline 16. Exhibit Traffic Builders Abelson-Taylor, Inc. Boehringer Ingelheim. Guanethidine guanidine guanfacine guaifenesin guanfacine guanabenz guanfacine guanidine guanidine guanethidine guanidine guanfacine Haltinonide Halcion Halcion halcinonide Halcion Haldol Halcion Healon Haldol Halcion Haldol Halog Halog Haldol Halotestin halothane halothane Halotestin Healon Halcion Heparin Hespan Hespan Heparin Humalog Humulin Humulin Humalog Hycodan Vicodin hydralazine hydroxyzine hydrochlorothiazide hydroflumethiazide hydrocodone hydrocortisone hydrocortisone hydrocodone hydrocortisone hydroxychloroquine hydroflumethiazide hydrochlorothiazide Hydrogesic hydroxyzine hydromorphone morphine hydroxychlorquine hydrocortisone hydroxyprogesterone medroxyprogesterone hydroxyurea hydroxyzine hydroxyzine hydralazine hydroxyzine Hydrogesic hydroxyzine hydroxyurea Hygroton Regroton Hytone Vytone Idamycin Adriamycin idarubicin daunorubicin idarubicin doxorubicin Iletin Lente Imdur Imuran imipramine desipramine Imodium Indocin Imodium Ionamin Imovax Imovax I.D. Imovax I.D. Imovax Imuran Elmiron Imuran Imdur Imuran Inderal indapamide iopamidol indapamide Iopidine Inderal Adderall Inderal Imuran Inderal Inderide Inderal Isordil Inderal 40 mg Enduronyl Forte Inderide Inderal Indocin Imodium Indocin Vicodin interferon 2 interleukin 2 interferon alfa-2a interferon alfa-2b interferon alfa-2b interferon alfa2ainterleukin 2 interferon 2 interleukin 2 interleukin 11 Intropin Isoptin Invanz Avinza iodamide indapamide iodapamide Iopidine iodine lopidine iodine Lodine Ionamin Imodium iopamidol indapamide Iopidine iodipamide Iopidine iodine Iopidine odine Ismelin Esimil Ismelin Isuprel isoflurane enflurane Isoptin Intropin Isopto Carbachol Isopto Carpine Isopto Carpine Isopto Carbachol Isordil Inderal Isordil Isuprel Isuprel Ismelin Isuprel Isordil Kaochlor K-Lor K-Dur Cardura Kefzol Cefzil Kemadrin Coumadin Klaron Klor-Con K-Lor Kaochlor Klor-Con Klaron K-Phos Neutral Neutra-Phos-K Lactose lactulose Lactulose lactose Lamictal Lamisil Lamictal Lomotil Lamisil Lamictal lamivudine lamotrigine lamotrigine lamivudine Lanoxin Levsinex Lanoxin Lonox Lantus Lente Lasix Lidex Lasix Luvox Lasix Luxiq Lente Iletin Lente Lantus Leukeran Alkeran Leukine Leukeran Leustatin lovastatin Levatol Lipitor Levbid Lithovbid Levbid Lorabid Levitra Lexiva Lexiva Levitra levothyroxine liothyronine Librax Librium Librium Librax Lidex Cidex Lidex Lasix Lioresal lisinopril liothyronine levothyroxine Lipitor Levatol lisinopril fosinopril lisinopril Lioresal Lithobid Levbid Lithobid Lithostat Lithobid Lithotabx Lithonate Lithostat Lithostat Lithobid Lithostat Lithonate Lithostat Lithotabs Lithotabs Lithobid Lithotabs Lithostat Livostin lovastatin Lodine codeine Lodine iodine Lodine lopidine Lomotil Lamictal Loniten Lotensin Lonox Lanoxin Lonox Loprox Loprox Lonox Lorabid Levbid Lorabid Lortab lorazepam alprazolam lorazepam clonazeam Lortab Cortef Lortab Lorabid Lotensin Loniten Lotensin lovastatin Lotrimin Lotrisone Lotrisone Lotrimin lovastatin Leustatin lovastatin Livostin lovastatin Lotensin Lovenox Lotronex Luminal Tuinal Lupron Lopurin Lupron Nuprin Luvox Lasix Luxiq Lasix Maalox Maolate Maalox Marax magnesium sulfate manganese sulfate manganese sulfate magnesium sulfate Maolate Maalox Maranox Marax Marax Atarax Marax Maalox Marax Maranox and dilantin. Antipsychotics: some clinical data suggests a possible pharmacodynamic and or pharmacokinetic interaction between serotonin specific reuptake inhibitors ssris ; and antipsychotics. Clonazepam fedexStopped 1 day prior to screening, Patient 329.009.00330 had taken pemoline for 1 day and stopped 7 days prior to screening, and Patient 329.012.00218 had taken clonaz4pam for 3 days and stopped 18 days prior to screening. Patient 329.004.00018 received diazepam for one day and patient 329.012.00027 received lorazepam for six days during the study. In the imipramine group, Patient 329.002.00057 tested positive for cannabis on a drug screen; however, the patient was authorized by the sponsor to continue in the study. Patient 329.012.00227 also tested positive for cannabis during the study. The number of patients in each treatment group with protocol deviations is summarized in Table 12. Clonazepam 1mg klonopin side effects klonopinAbstract Two types of benzodiazepine binding sites for [3H]diazepam in mammalian central nervous tissue were identified using selective in vitro tissue culture and in situ kainic acid lesion techniques. These two binding sites were pharmacologically distinguished by differential displacement of the [3H]diazepam radioligand using the centrally active benzodiazepine, clonazepam, and the centrally inactive benzodiazepine, R05-4864. Clonazepam-displaceable binding sites were found to be located principally on neuronal membranes, while R05-4864-displaceable binding sites were found to be located on non-neuronal elements. These pharmacological distinctions can be used to characterize the predominant cell types which bind benzodiazepines in nervous tissue. It is suggested that one quantitative measure of different cell populations is the ratio of clonazepam- to R05-4864-displaceable [3H]diazepam binding within a single neuronal tissue sample. Sented chronic ischemic changes. An electroencephalogram EEG ; showed slow sharp waves in the area of the surgical resection but no epileptiform activity or other abnormal patterns. Low-dose haloperidol was administered from the beginning of Ms. A's stay in the psychiatry unit and was tapered off by the time of discharge. Throughout her hospital stay, her manic and psychotic symptoms gradually dissipated. At the time of discharge, Ms. A was taking clonazepam, 0.5 mg b.i.d., which was tapered and discontinued after discharge. Her family members reported that her disposition at the time of discharge was somewhat brighter than her baseline but not remarkably so. Most users begin taking the drug orally but because of the slow onset of action 30-60 minutes ; and the development of tolerance, intravenous use becomes more and more attractive. MEDICATION GUIDELINES MEDICATION TERMINOLOGY The terminology to be followed in this document is as follows: PSYCHOTROPIC MEDICATIONS The broad designation for the group of medications used in treating mental disorders. ANTIPSYCHOTIC MEDICATIONS Antipsychotic, or neuroleptic, medications are used in the treatment of psychotic disorders. The older, typical antipsychotics e.g., haloperidol, thorazine ; have a high frequency of side effects, especially extrapyramidal side effects EPS ; . The newer, atypical antipsychotics e.g., olanzapine, risperidone ; tend to cause fewer side effects, including less EPS. Clozapine has been shown to be more effective than other antipsychotics in treatment-resistant schizophrenia. MOOD STABILIZER MEDICATIONS A variety of medications are now used in the treatment of unstable moods in bipolar and related disorders. These medications are sometimes referred to as antimanics. o Lithium is a cationic salt useful for the management of acute mania and certain schizoaffective conditions and as a prophylactic agent in selected bipolar and unipolar disorders. o Carbamazepine, valproic acid, gabapentin, and lamotrigine are anticonvulsant medications sometimes used in the treatment of bipolar disorders and aggressive impulsive symptoms. o Clomazepam is a benzodiazepine, which is reported to have antimanic and antianxiety properties. This agent is sometimes used as adjunctive treatment for acute manic episodes. ANTIDEPRESSANT MEDICATIONS Antidepressant medications are commonly used for the alleviation of depression. This group of drugs includes the heterocyclic antidepressants, selective serotonin reuptake inhibitors SSRI's ; , other single dual neurotransmitter action agents, and monoamine oxidase MAO ; inhibitors. Some antidepressants are also used in the treatment of OCD, ADHD, generalized anxiety disorder, social phobia, panic disorder, and eating disorders. ANXIOLYTIC MEDICATIONS Anxiolytic medications are used for the reduction or control of anxiety. This class includes some benzodiazepines, antihistamines, and buspirone. HYPNOTIC MEDICATIONS The term hypnotic agent refers to the class of psychotropic medications whose primary action is the promotion of sleep. This class of compounds includes certain benzodiazepines, zolpidem, zaleplon, barbiturates, and chloral hydrate. The latter two should rarely be used since safer alternatives are available. Rev. 5 2000 Page 1-4. Clindets . Clinoril . Clobetasol Propionate . Clobetasol Propionate Foam . Clobetasol Propionate Emollient . Clobex . Cloderm . Cloderm Cream 0.10% Clofazimine . Clofibrate . Clomid . Clomiphene Citrate . Clomipramine HCl . Clonazepam . Clonidine HCl . Clonidine HCl Patch . Clonidine HCl Patch, Transdermal Weekly . Clonidine HCl Tablet . Clopidogrel Bisulfate . Clorazepate Dipotassium . Clorpres . Clorthalidone . Clotrimazole . Clotrimazole Troche . Clotrimazole Betamethasone . Clotrimazole Betamethasone Dipropionate . Clotrimazole Betamethasone Dipropionate Cream . Clotrimazole Betamethasone Dipropionate Lotion . Clozapine . Clozaril . Coagulation Therapy . Codal-DH Codeine APAP Caffeine Butalb . Codeine Phosphate Acetaminophen . Codeine Phosphate Aspirin . Codeine Phosphate Aspirin Caffeine Butalbital . Codeine Sulfate . Codeine Sulfate . Codiclear DH Codimal DH Codimal pH Codituss DH Cogentin . Cognex . Colazal . Colchicine . Colchicine . Coldcough PD Colesevelam HCl . Colestid . Coly-Mycin S . Coly-Mycin S Suspension, Drops . Colyte . Combination Anticholinergics . Combination Narcotic Analgesics . Combipatch . Combivent . Combivir . Combunox . Compazine . Comtan . Concerta . Condylox . Conison . Contrin . Copaxone . Copegus . Cordarone . Cordran Adhesive Patch . Cordran Lotion . Cordran Ointment . Cordran SP Cordran Tape . Cordran Tape 4mcg sq cm . Coreg . Corgard . Cortane-B Cortef . Cortef 20mg Cortenema . Corticosteroids . Cortifoam . Cortisone Acetate . Cortisone Acetate . 12, 37.
|